Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

NCT06884670 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

130

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer

Interventions

DRUG: Interleukin-2
RADIATION: Radiotherapy
DRUG: Tislelizumab
DRUG: Oxaliplatin
DRUG: Capecitabine

Sponsor

The First Affiliated Hospital with Nanjing Medical University